PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) named President Carolyn Bonner as its new chief financial officer, formalizing a role she has held on an interim basis since September and consolidating senior operational and financial leadership as the company advances its dermatology and oncology pipeline.
Bonner succeeds co-founder Jim Quinlan, who resigned for health reasons. Quinlan helped steer Medicus through its reverse takeover of SkinJect and its 2024 Nasdaq listing. The company said he will transition duties to Bonner over the coming weeks.
Executive Chairman and CEO Dr. Raza Bokhari said Bonner has already been providing “strong financial leadership” since assuming acting CFO duties. He added that combining the president and CFO roles is intended to reinforce alignment across strategic, operational and financial priorities as Medicus scales its clinical development programs.
Bonner brings nearly two decades of experience in healthcare and life sciences, including roles in executive management, operations and corporate development. Before joining Medicus, she served as CEO of PCL, Inc., a CAP-accredited specialty laboratory with operations in the U.S. and the UAE. She previously held business development positions at Rosetta Genomics and Inform Diagnostics. Bonner holds a marketing degree from West Chester University of Pennsylvania.
In her expanded role, Bonner will oversee financial reporting, capital markets strategy, budgeting, forecasting, treasury functions and cross-functional planning across development and commercial initiatives.
The leadership announcement comes as Medicus reports steady progress across its SkinJect clinical programs. The company is conducting a Phase 2 study of SKNJCT-003 at nine U.S. sites using dissolvable microneedle arrays to treat basal cell carcinoma. An interim look released earlier this year showed more than 60 percent clinical clearance, though the company emphasized the findings remain preliminary. Regulatory feedback from the FDA in September supported a potential 505(b)(2) pathway for future submissions.
Medicus also began patient dosing in the United Arab Emirates in October under a separate 36-patient study, with Cleveland Clinic Abu Dhabi serving as principal investigator. In November, the company secured full regulatory and ethical approvals in the United Kingdom to expand its Phase 2 program, clearing requirements from the MHRA, HRA and Wales Research Ethics Committee.
The company continues to broaden its platform through partnerships and acquisitions. A memorandum of understanding with Boston-based Helix Nanotechnologies will explore the co-development of thermostable infectious disease vaccines using a proprietary mRNA platform. Medicus also acquired Antev Limited, a U.K. biotech developing Teverelix, a next-generation GnRH antagonist intended for cardiovascular high-risk prostate cancer patients and those with recurring acute urinary retention.
In October, Medicus formed a collaboration with the Gorlin Syndrome Alliance to support compassionate access to SkinJect for patients with difficult-to-treat basal cell carcinoma. The initiative is expected to create an expanded-access pathway while generating real-world data to support future regulatory filings.
Medicus said the appointment of Bonner strengthens executive continuity as the company scales clinical operations and advances multiple late-stage assets.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.